Symbio Pharmaceuticals Limited (JP:4582)
:4582
4582 Stock Chart & Stats
¥90.00
¥6.00(2.96%)
At close: 4:00 PM EST
¥90.00
¥6.00(2.96%)
Day’s Range― - ―
52-Week Range¥81.00 - ¥229.00
Previous CloseN/A
Volume447.50K
Average Volume (3M)577.10K
Market Cap
¥7.08B
Enterprise Value¥4.90B
Total Cash (Recent Filing)¥3.05B
Total Debt (Recent Filing)¥1.30B
Price to Earnings (P/E)―
Beta0.84
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-21.66
Shares Outstanding59,567,080
10 Day Avg. Volume434,010
30 Day Avg. Volume577,100
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Specialty Pharmaceutical Portfolio (oncology/hematology)Symbio’s focused specialty-pharma model—development, manufacturing/marketing and distribution concentrated on oncology and hematology, including marketed products such as TREAKISYM—creates durable clinical demand, regulatory barriers and customer stickiness that support recurring sales and long-term market positioning.
Diversified Revenue Mix: Product Sales Plus Licensing/collaborationsA business model that combines product sales with licensing and collaboration income provides durable optionality: upfronts and milestones can smooth funding, royalties create long-running cash streams, and partnerships share R&D and commercialization risk—supporting resilience over a multi-month to multi-year horizon.
Strong Gross Margins And Meaningful Asset BaseReported strong gross margins and a meaningful asset base indicate favorable product-level economics and tangible capacity (manufacturing/supply) that can underpin recovery. If SG&A and R&D spending are rebalanced, high gross margins provide a structural path to restore profitability and cash generation over months.
Bears Say
Multi-year Revenue DeclineSustained top-line declines across 2023–2025 shrink scale, reduce pricing leverage and weaken the economics of marketed products. Continued revenue contraction limits reinvestment in commercialization and R&D, risks partner disengagement, and makes returning to durable growth dependent on new product or deal catalysts.
Persistent Negative Operating And Free Cash FlowMaterial negative operating and free cash flows over multiple years force reliance on external financing or asset sales. This worsens liquidity risk, can drive dilution or higher-cost debt, and constrains sustainable funding for late-stage trials, commercialization and strategic investments absent a clear near-term improvement in cash generation.
New Leverage And Equity ErosionThe emergence of ~¥2.0B debt after years of zero leverage materially raises financial risk. Debt above equity and compressed shareholders' equity reduce the company’s buffer against shocks, increase interest and refinancing obligations, and limit strategic flexibility for investments or licensing deals if operating losses persist.
Symbio Pharmaceuticals Limited News
4582 FAQ
What was Symbio Pharmaceuticals Limited’s price range in the past 12 months?
Symbio Pharmaceuticals Limited lowest stock price was ¥81.00 and its highest was ¥229.00 in the past 12 months.
What is Symbio Pharmaceuticals Limited’s market cap?
Symbio Pharmaceuticals Limited’s market cap is ¥7.08B.
When is Symbio Pharmaceuticals Limited’s upcoming earnings report date?
Symbio Pharmaceuticals Limited’s upcoming earnings report date is May 07, 2026 which is in 39 days.
How were Symbio Pharmaceuticals Limited’s earnings last quarter?
Symbio Pharmaceuticals Limited released its earnings results on Feb 05, 2026. The company reported -¥21.66 earnings per share for the quarter, missing the consensus estimate of N/A by -¥21.66.
Is Symbio Pharmaceuticals Limited overvalued?
According to Wall Street analysts Symbio Pharmaceuticals Limited’s price is currently Overvalued.
Does Symbio Pharmaceuticals Limited pay dividends?
Symbio Pharmaceuticals Limited does not currently pay dividends.
What is Symbio Pharmaceuticals Limited’s EPS estimate?
Symbio Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Symbio Pharmaceuticals Limited have?
Symbio Pharmaceuticals Limited has 59,567,080 shares outstanding.
What happened to Symbio Pharmaceuticals Limited’s price movement after its last earnings report?
Symbio Pharmaceuticals Limited reported an EPS of -¥21.66 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.176%.
Which hedge fund is a major shareholder of Symbio Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in JP:4582
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Wakamoto Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Medrx Co., Ltd.
―